Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event

SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.
JD Supra

FinCEN Proposes New Rule Introducing Reforms to AML/CFT Programs

On April 7, 2026, the U.S. Department of Treasury’s Financial Crimes Enforcement Network (FinCEN) issued a notice of proposed rulemaking ...
JD Supra

FinCEN Issues Proposed Rule Revising the AML Program Requirements for Financial Institutions

On April 7, 2026, the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN) issued a long-awaited new Notice of ...
The American Journal of Managed Care

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Targeted Oncology

Positive Topline Results Demonstrated for LYT-200 in MDS, AML

LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...